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ABSTRACT 
 
Hemoglobin Bart’s (γ4), an abnormal Hb, is a homotetramer of  γ-globin chains .  Τhe amount of this abnormal Hb in blood 
circulation can be used as an indicator for the presence of different genotypes of α-thalassemias.  We successfully cloned and 
expressed a novel recombinant scFv antibody derived from mouse hybridoma producing monoclonal antibody highly specific to 
Hb Bart’s.  The genes encoding variable regions of the heavy (VH) and light (VL) chains were cloned and identified by DNA 
sequencing.  The VH and VL genes were connected via a short linker to form the full length VH-linker-VL construct and ligated 
into pET28a.  The His tag-scFv fusion protein was expressed in E. coli and purified by affinity chromatography.  The 
recombinant scFv antibody was mostly expressed as inclusion bodies with the predicted molecular weight of 28 kDa.  This scFv 
antibody was very specific by reacting with Hb Bart’s (γ4) but not cross-react with HbA (α2β2), HbF (α2γ2), HbS (α2β2S), HbE 
(α2β2E), HbA2 (α2δ2), and HbH (β4), as determined by Western blot.  The detection sensitivity of this scFv antibody was 5 µg/µl 
of Hb Bart’s by dot blot ELISA.  The scFv antibody should be useful in development of an immunoassay with high sensitivity 
and specificity for the diagnosis of α-thalassemias. 
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Introduction 
 
 
α-Thalassemias are major health problem in the 
Mediterranean countries,the Middle East, Southern 
China, India, and Southeast Asia especially Thailand 
[1].  It is a genetic disorder caused by the reduction of 
α-globin chain synthesis resulting in the formation of 
the abnormal homotetramer hemoglobins including 
HbH (β4) and Hb Bart’s (γ4).  HbH disease, the 
outcome of the interaction of α0- and α+-thalassemia 
carriers, is the moderate severe form with marked 
hypochromia and microcytosis.The interaction between  
α
0
-thalassemia carriers leads to the most severe type, 
Hb Bart’s hydrops fetalis which die 
in utero or soon after birth because the highest affinity 
O2 binding of Hb Bart’s results in severe hypoxia [2].  
One major way to prevent the spreading of the severe 
α-thalassemia diseases, including HbH disease and Hb 
Bart’s hydrops fetalis, is to identify α-thalassemia 
carriers and subsequent genetic counseling.  At present,  
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standard methods such as polymerase chain reaction 
(PCR) [3-5] or DNA hybridization [6, 7] to identify α-
thalassemia carriers require expensive equipments and 
tedious laboratory intervention.  These methods are not 
suitable for screening large populations and therefore, 
one easy and practical method such as antigen-antibody 
based assay needs to be developed.Hb Bart’s in blood 
circulation is an indicator of α-thalassemia carriers [2].   
The quantity of Hb Bart’s in cord blood usually 
correlates well with the α-thalassemia genotypes [8-
11].  Low level in 1-2% range of Hb Bart’s reflect 
heterozygous state for +-thalassemia.  Higher level in 
4-10% indicate the heterozygous state for -
thalassemia or homozygous + thalssemia.  Level of 
12% suggest HbH disease and level up to 70-80% was 
found in Hb Bart’s hydrops fetalis [2].  However, the 
amount of Hb Bart’s decreases with age [12], and trace 
amount of Hb Bart’s in adult blood is normally 
undetectable by routine hemoglobin electrophoresis.  
The more sensitive methods involved antibody against  
Hb Bart’s, such as rabbit polyclonal antibody coupled 
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with radioimmunoassay were previously reported by 
our research group [13, 14].  However, low specificity 
and batch-to-batch variation of rabbit polyclonal 
antibody limited their applications.  To overcome the 
limitation of using rabbit polyclonal antibody, 
monoclonal antibodies (mAb) specific to  
Hb Bart’s (hybridoma clone 2D4) was firstly established 
in our laboratory and successfully applied for the 
detection of Hb Bart’s in α-thalassemia blood samples 
[15].  Methods involving mAb specific to Hb Bart’s for 
the detection of -thalassemias have been further 
developed, including sandwich ELISA [16, 17], ELISA 
strip test [18], and sandwich immunochromatographic 
strip test [19]. Although, mAb with high sensitivity and 
specificity to Hb Bart’s was successfully used, 
however, there are considerations about the cost of 
large scale antibody production, purification, and long-
term storage.   Recombinant antibody technology in 
bacterial cells offers a low-cost, high recovery yield, 
and reasonable binding affinity alternative to antibody 
production [20-22].  Therefore, recombinant antibody 
technology is a good alternative means to overcome all 
the mentioned problems.  This research study aims to 
clone and express  a novel recombinant scFv antibody 
against Hb Bart’s using the variable domains of 
immunoglobulin VH and VL chains derived from a 
mouse hybridoma producing mAb highly specific to 
Hb Bart’s.  The specificity and sensitivity of this 
recombinant scFv antibody were determined for the 
possibility of developing an immunoassay for the 
detection of α-thalassemias. 
 
Materials and Methods 
 
Reagents, vectors, bacterial strains, and enzymes 
 
All reagents were purchased from well established 
companies:  Iscove’s Modified Dulbecco’s Medium 
(IMDM) and fetal bovine serum (FBS) were purchased 
from Gibco, USA; RNeasy mini kit from Qiagen, 
Germany; RobusT Ι RT-PCR kit and DNA polymerase 
from Finnzymes, Finland; PCR clean-up gel extraction 
kit from Macherey-Nagel, Germany; pGEM-T vector 
from Promega, USA; pET28a vector, E. coli strain 
TOP10F and BL21(DE3), nickel-nitrilotriacetic acid 
(Ni-NTA) resin from Novagen, USA; Nde Ι and BamH 
Ι from Amersham, USA; lysozyme from Armesco, 
USA; Horseradish peroxidase (HRP) conjugated mouse 
anti-His-tag mAb from USBiological, USA; HRP 
conjugated rabbit anti-mouse Igs from Dako, Denmark; 
standard hemoglobin S from Sigma, USA.  Standard 
hemoglobins; A, F, E, A2, and HbH disease and Hb 
Bart’s hydrops fetalis hemolysate were obtained in our 
previous works [15, 17, 18].  Primers were synthesized 
by Bio Basic Inc., Canada.  DNA sequences were 
commercially analyzed by dye termination method 
from Applied Biosystems, USA.  All other common 
chemicals are of molecular biology grade. 
 
RNA isolation and antibody gene amplification 
 
Mouse hybridoma (clone 2D4) producing mAb highly 
specific to Hb Bart’s [15] was grown in IMDM 
supplemented with 20% FBS and incubated at 37°C, 
5% CO2 for 2 days.  Total RNA was isolated from 106 
hybridoma using RNeasy mini kit.  Complementary 
DNA was subsequently synthesized by RobusT Ι RT-
PCR kit and used as template for the VH and VL gene 
amplification by the established antibody-specific 
primers [23].  The amplification profiles were as 
follows; denaturation of RNA secondary structure at 
65°C for 5 min, reverse transcription at 48°C for 30 
min, 30 cycles of 94°C for 30 s; 50°C for 30 s; 72°C 
for 1 min, and final extension at 72°C for 7 min.  The 
amplified products were purified by PCR  
clean-up gel extraction kit, ligated into pGEM-T vector 
and transformed into E. coli TOP10F.  Colony PCR 
was performed for screening of the inserted gene using 
universal T7 and SP6 primers.  Ten positive colonies of 
either VH or VL gene inserted were randomly selected 
for direct DNA sequencing.  Complementarity 
determining regions (CDRs) of VH and VL chains were 
identified using Kabat and Chothia numbering scheme 
(http://www.bioinf.org.uk/abs/). 
 
Construction of scFv gene 
 
DNA manipulation was based on the standard methods 
[24].  The VH and VL genes were amplified, and linked 
together to form the full length VH-linker-VL scFv gene 
construct by splice overlapped extension-polymerase 
chain reaction (SOE-PCR).  Primers containing Nde Ι 
and BamH Ι restriction sites, peptide linker (Gly4Ser)3, 
and a stop codon were designed for cloning into 
pET28a expression vector (Table 1).   
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Table 1: Primers designed for construction of the full length scFv gene 
 
Primers Sequence Annealing T° 
 
VH 
forward 
 
VH 
reverse 
 
 
VL 
forward 
 
 
VL 
reverse 
 
 
5′-GCGCATATGCAGGTTCAGCTGCAGCAGTCTGGG-3′ 
 
 
5′-GGAGCCGCCGCCGCCAGAACCACCACCACCGGAGGA- 
GACGGTGACTGA-3′ 
 
 
5′-GGCGGCGGCGGCTCCGGTGGTGGTGGTTCAATTGTG- 
ATGACCCAGTCT-3′ 
 
 
5′-CGCGGGATCCTTATTTCCA GCTTGGTCCCCCCTC-3′ 
 
 
72°C 
 
 
81°C 
 
 
 
78°C 
 
 
 
73°C 
VH forward primer contained the Nde Ι restriction site (underlined).  VH reverse and VL forward primers contained 
the linker sequence(italic).VL reverse primer contained the BamH Ι restriction site (underlined) and a stop codon 
(bold). 
 
PCR conditions were as follows: initial denaturation at 
98°C for 30 s, 30 cycles of 98°C for 10 s; 72°C for 25 s, 
with final extension at 72°C for 10 min.  The amplified 
products were digested with Nde Ι and BamH Ι, gel 
purified, and ligated into pET28a as shown in Figure 1.  
After incubation, the ligation product was transformed 
into E. coli BL21(DE3).  Colony PCR was conducted for 
screening of inserted scFv gene using T7 promoter and T7 
terminator primers.  The integrity of the full length scFv 
gene was confirmed by DNA sequencing.   
 
Expression of recombinant scFv antibody 
 
E. coli BL21(DE3) carrying the full length scFv gene 
were cultured in 1 liter of  
Luria-Bertani (LB) medium containing 30 µg/ml 
kanamycin at 37°C with shaking at 200 rpm until the 
OD600 reached to 0.6-0.8.  For induction of scFv gene 
expression, a final concentration of 1 mM isopropyl β-D-
thiogalactopyranoside (IPTG) was added and incubated 
with shaking at 37°C for 4 h.  Bacterial cells were pelleted 
by centrifugation at 4,000 rpm, 4°C for 20 min, washed 
once with 40 ml of 50 mM Tris-HCl pH 8.0 and stored at 
-70°C until use.  To analyze the recombinant protein 
expression, we performed Western blot analysis.  Proteins 
of IPTG-induced and un-induced in bacterial cell lysate 
were analyzed by 12% SDS-PAGE [25] and blotted onto a 
PVDF membrane using Trans-Blot semi-dry 
electrophoretic transfer cell.  The membrane was blocked 
with 10% (w/v) skim milk at room temperature for 2 h.  
After washing 3 times with PBS-0.05% Tween 20 (PBS-
T),  
the membrane was incubated with HRP conjugated mouse 
anti-His-tag mAb (1:1,000) at room temperature for 1 h.  
After washing, 4-chloro-1-naphthol substrate was added 
and the color reaction was subsequently developed at 
room temperature for 10-15 min.  The reaction was 
stopped by repeatedly washing with distilled water. 
 
Purification and refolding of recombinant scFv 
antibody 
 
Four grams of bacterial cell pellet were resuspended in 80 
ml of lysis buffer (50 mM Tris-HCl pH 8.0, 1 mM β 
mercaptoethanol, 1 mg/ml lysozyme) and incubated  
at room temperature for 30 min.  Bacterial cells were 
added with final concentration of 1% Triton X-100 
and 0.5 M NaCl and incubated at room temperature for 
another 30 min.  After sonication, inclusion bodies were 
collected by centrifugation at 14,000 rpm, 4°C for 20 min.  
The inclusion bodies were washed with 30 ml of 50 mM 
Tris-HCl pH 8.0 for 3 times, solubilized in 100 ml of 8 M 
urea, 50 mM Tris-HCl pH 8.0, 1 mM phenylmethyl 
sulfonyl fluoride (PMSF) and purified under denaturing 
conditions by 20 ml Ni-NTA resin affinity 
chromatography  
according to the manufacturer’s instructions.  After 
purification, recombinant protein was renatured in redox 
refolding buffer (0.1 M Tris-HCl pH 7.4, 0.4 M L-
arginine, 0.2 mM PMSF, 0.5 mM oxidized glutathione, 5 
mM reduced glutathione) [26] and stirred at 4°C 
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overnight.  After centrifugation at 12,000 rpm, 4°C for 20 
min, the aggregated protein precipitated and was 
discarded.  The refolded recombinant scFv antibody in 
supernatant fluid was concentrated using Centriprep 
centrifugal filter.  The refolded scFv antibody was 
dialyzed against PBS at 4°C overnight.  The protein was 
quantified using Bradford assay [27] and evaluated by 
SDS-PAGE.  
 
Determination of specificity 
 
Specific binding of the recombinant scFv anti-Hb Bart’s 
was investigated by Western blot analysis.  Parent mAb 
(clone 2D4) specific to Hb Bart’s was included as a 
positive control.  Fifty micrograms of each standard 
hemoglobin (HbA, HbF, HbS, HbE, or HbA2), and 
approximately 120 µg of HbH disease and Hb Bart’s 
hydrops fetalis hemolysates, were run in 12% native-
PAGE.  The gel was blotted onto a nitrocellulose 
membrane and blocked with 10% (w/v) skim milk at room 
temperature for 2 h.  After washing, the membrane was 
incubated with 100 µg/ml of the purified scFv antibody at 
room temperature for 1 h.  The following processes were 
conducted as previously described.  
 
Determination of sensitivity 
 
Sensitivity of the recombinant scFv antibody against Hb 
Bart’s was analyzed by dot blot ELISA.   
One microliter, of serial 2-fold dilutions of Hb Bart’s 
hydrops fetalis hemolysate with the final concentration of 
Hb Bart’s of 40-0.31 mg/ml, was spotted onto a 
nitrocellulose membrane.  Therefore, each spot contains 
40, 20, 10, 5, 2.5, 1.25, 0.63 and 0.31 µg of Hb Bart’s 
respectively.  The membrane was subsequently blocked 
with 10% (w/v) skim milk, washed with PBS-T, and 
incubated with 100 µg/ml of the purified scFv antibody at 
room temperature for 1 h.  After washing, the membrane 
was then incubated with HRP conjugated mouse anti-His-
tag mAb (1:500) at room temperature for 1h. Finally, 4-
chloro-1-naphthol substrate was added and color reaction 
was developed as previously described. 
 
Results and Discussion 
 
Construction of scFv gene and sequence analysis  
 
Total RNAs from the mouse hybridoma (clone 2D4), 
secreting mAb highly specific to  
Hb Bart’s, were isolated and then RT-PCR to obtain 
cDNA for the construction of VH and VL genes.  Selection 
of VH and VL genes from cDNA of mouse hybridoma, we 
separately amplified the cDNA, inserted into pGEM-T 
vector, analyzed the DNA sequences, and identified the 
CDRs.  The results indicated that all of ten VH gene 
sequences were identical whereas two populations of VL 
gene were observed.  One of the VL populations (5/10), 
deduced amino acid sequences represented the premature 
termination and causing of shortened polypeptide 
products.  The deduced amino acid sequences of the other 
population (5/10)
 
were retrieved from translated 
nucleotides and subsequently aligned  
with available sequences in GenBank public database 
using BLAST program 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi).  Interestingly, 
amino acid sequences of the latter VL were identical to 
mouse anti-chloramphenicol immunoglobulin kappa light 
chain variable region (accession no. ACV40677), and 
anti-hTERT single-chain variable fragment (99%) 
(accession no. ABW90123).  The VH and VL genes were 
individually reamplified, and assembled into a full length 
scFv by SOE-PCR.  The reamplified products of VH, VL, 
and full length scFv genes were shown in Figure 2.  The 
reamplified product of VH was 402 bp  
(Figure 2, lane 1) derived from the initial product of 363 
bp, 9 bp Nde Ι restriction site and  
30 bp linker.  The product of VL was 364 bp (Figure 2, 
lane 2) came from the initial product of 321 bp, 10 bp 
BamH Ι restriction site, 3 bp stop codon and 30 bp linker.  
The full length scFv gene was 751 bp (Figure 2, lane 3) 
composed of the VH (402 bp) and VL (364 bp) subtracted 
by 15 bp complementary linker between VH and VL.  The 
full length scFv gene was then inserted into pET28a 
expression vector locating after His-tag sequence.  The 
DNA sequence and deduced amino acid sequence of the 
His-tag-scFv fusion protein was shown in Figure 3.  The 
three VH CDRs (CDR-H1, H2 and H3), same as three VL 
CDRs (CDR-L1, L2 and L3), are also indicated.  The 
DNA sequence and deduced amino acid sequence of scFv 
(VH-linker-VL format) were also submitted to GenBank 
public database (accession no. KF663616). 
 
Expression and purification of recombinant scFv 
antibody 
 
The expressed proteins, and the purified recombinant scFv 
antibody were analyzed by SDS-PAGE and Western blot 
analysis.  Analysis of proteins from the IPTG-induced and  
un-induced bacterial cell lysate, soluble fraction of 
bacterial cell lysate, inclusion bodies, and purified 
recombinant scFv antibody were shown in Figure 4.  After 
IPTG induction of E. coli, the recombinant protein was 
mostly expressed as inclusion bodies with predicted 
molecular weight of approximately 28 kDa (Figure 4A, 
lanes 2, 4, 5, and Figure 4B1-B2, lane 2).  The 
recombinant scFv antibody was in the precipitate (Figure 
4A, lane 2) but not in the supernatant fluid (Figure 4A, 
lane 3) of the bacterial cell lysate from the IPTG-induced 
E. coli while the precipitate of bacterial cell lysate of the 
un-induced bacteria had no recombinant scFv antibody 
(Figure 4A, lane 1).  It was clearly shown that the scFv 
antibody should be in the inclusion bodies of the bacterial 
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cells.  Although, the expression of recombinant proteins in 
E. coli can be in soluble form or in inclusion bodies 
depending on the nature of proteins or the expression 
system [26, 28].  However, most of recombinant scFv 
antibody tends to form inclusion bodies when expressed 
in E. coli [29-31].  The scFv antibody was further purified 
by Ni-NTA affinity chromatography under denaturing 
condition and directly refolded in redox refolding buffer.  
Approximately 1 mg of refolded recombinant scFv 
antibody was recovered from 1 liter of bacterial culture.  
However, the refolding and recovery efficiency from 
various studies were varied in different recombinant 
antibodies [32-35].   
 
Specificity and sensitivity of recombinant scFv 
antibody  
 
The native-PAGE of hemoglobins was either stained with 
Coomassie brilliant blue (Figure 5A) or blotted onto a 
nitrocellulose membrane (Figure 5B).  The specific 
binding of scFv antibody to Hb Bart’s was determined by 
Western blot analysis.  Results revealed that the scFv 
antibody could bind specifically to Hb Bart’s (γ4) (Figure 
5B, lanes 1 and 8) without cross-reactivity to HbA (α2β2), 
HbF (α2γ2), HbS (α2β2S), HbE (α2β2E), HbA2 (α2δ2), and  
HbH (β4) (Figure 5B, lanes 2-7).  Similar results were 
observed when specificity test was undertaken in the 
parent mAb (clone 2D4) (data not shown).  It was clearly 
shown that the recombinant scFv antibody only react to 
the specific folding region of the tetrameric γ4 globin 
chains in Hb Bart’s but not any folding regions or side 
chains of the dimeric γ2 globin chains in HbF.  The 
recombinant scFv antibody generated in this study was 
highly specific to Hb Bart’s comparable to its parent 
mAb.Dot blot ELISA was developed for quantitative 
determination of Hb Bart’s to determine the sensitivity of 
the recombinant scFv antibody.  The detection sensitivity 
of Hb Bart’s by the scFv antibody was 5 µg/µl as 
indicated in Figure 6.  Same results were obtained when 
using the parent mAb (data not shown).  The detection 
sensitivity of scFv antibody is quite interesting for the 
determination of   α0-thalassemia carriers.  Previous report 
of Munkongdee et al. [9] showed that the level of Hb 
Bart’s in cord blood of   17 cases α0-thalassemia carriers 
were 6.2 µg/µl (4.6% of Hb Bart’s in 134 g/L Hb).  
Fucharoen et.al. [36] reported the level of Hb Bart’s in 
cord blood of  9 cases α0-thalassemia carriers were 12.2 
µg/µl (9.2% of Hb Bart’s in 133 g/L Hb).  From these 
results, we are attempting to develop an immunoassay 
screening test for determination of α-thalassemia using the 
recombinant scFv antibody. The ability to identify  α0-
thalassemia carriers and HbH disease in infants will be 
very useful for health care of the affected children.  When 
the identification of α-thalassemias was coupled with 
appropriate genetic counseling, it is also very helpful for 
the family planning to prevent or avoid having α-
thalassemia disease children. 
                          
Fig 1:Expression vector map of 
pET28a-scFv anti-Hb Bart’s.   
 
Fig 2:Splice overlapped extension-
PCR (SOE-PCR) for construction of 
the full length scFv antibody 
encoding gene.   
Fig 3:DNA sequence and deduced 
amino acid sequence of the His-tag-
scFv fusion protein.   
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Fig4:Analysis of expression and 
purification of the recombinant 
scFv anti-Hb Bart’s.   
Fig 5:Analysis of specific binding 
of the recombinant scFv anti-Hb 
Bart’s.   
 
Fig6:Dot blot ELISA for 
sensitivity determination of the 
recombinant scFv anti-Hb 
Bart’s.
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